Cooperative Stimulation of Dendritic Cells by Cryptococcus neoformans Mannoproteins and CpG Oligodeoxynucleotides by Dan, Jennifer M. et al.
Cooperative Stimulation of Dendritic Cells by
Cryptococcus neoformans Mannoproteins and CpG
Oligodeoxynucleotides
Jennifer M. Dan
1,2, Jennifer P. Wang
2, Chrono K. Lee
2, Stuart M. Levitz
1,2*
1Department of Microbiology and Immunology Training Program, Boston University School of Medicine, Boston, Massachusetts, United States of America, 2Division of
Infectious Diseases, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Abstract
While mannosylation targets antigens to mannose receptors on dendritic cells (DC), the resultant immune response is
suboptimal. We hypothesized that the addition of toll-like receptor (TLR) ligands would enhance the DC response to
mannosylated antigens. Cryptococcus neoformans mannoproteins (MP) synergized with CpG-containing oligodeoxynucleo-
tides to stimulate enhanced production of proinflammatory cytokines and chemokines from murine conventional and
plasmacytoid DC. Synergistic stimulation required the interaction of mannose residues on MP with the macrophage
mannose receptor (MR), CD206. Moreover, synergy with MP was observed with other TLR ligands, including tripalmitoylated
lipopeptide (Pam3CSK4), polyinosine-polycytidylic acid (pI:C), and imiquimod. Finally, CpG enhanced MP-specific MHC II-
restricted CD4
+ T-cell responses by a mechanism dependent upon DC expression of CD206 and TLR9. These data suggest a
rationale for vaccination strategies that combine mannosylated antigens with TLR ligands and imply that immune responses
to naturally mannosylated antigens on pathogens may be greatly augmented if TLR and MR are cooperatively stimulated.
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Introduction
Pattern recognition receptors (PRRs) recognize evolutionarily
conserved molecular motifs on pathogens. PRRs are employed by
the host immune system to evoke an immediate response to the
invading pathogen through the production of inflammatory
cytokines and chemokines. Because of the efficiency of this
response, PRRs are attractive candidates as adjuvants for vaccines.
PRRs span a broad range of receptors including Toll-like receptors
(TLRs), carbohydrate-binding calcium-dependent type lectin
receptors (CLRs), nucleotide binding oligomerization domain like
receptors and intracellular viral receptors [1].
The 11 human TLRs and 13 mouse TLRs [2] are membrane-
bound receptors which recognize pathogen-associated molecular
patterns (PAMPs). TLRs can be either expressed on the cell
surface (e.g., TLRs 1,2,4) or on endosomal vesicles (TLRs 3, 7-9).
One particular TLR agonist undergoing clinical trials is synthetic
cytosine phosphate guanine (CpG)-containing oligodeoxynucleo-
tides (ODN) [3]. CpG is taken up by cells in a clathrin-dependent
manner and binds to TLR9 which is recruited from the
endoplasmic reticulum to the endosome [4]. This triggers the
cytoplasmic Toll-IL-1R domain of TLR9 to bind to the adapter
molecule, myeloid differentiation marker 88 (MyD88) [5]. MyD88
diverges into two signaling pathways, one mediated by NF-kB
activation and one mediated through interferon regulatory factor
(IRF) 7 activation [6].
CLRs recognize particular carbohydrate residues via their
extracellular carbohydrate recognition domain. CLRs function
both in leukocyte trafficking and antigen recognition [7]. Distinct
cytoplasmic motifs on CLRs mediate signaling and trafficking into
vesicles. For example, the macrophage mannose receptor (MR,
CD206), traffics to early endosomes while the dendritic cell
ICAM3-grabbing non-integrin (DC-SIGN, CD209) traffics to late
endosomes and early lysosomes [8]. MR preferentially recognizes
terminal mannose residues while DC-SIGN recognizes internal
mannose residues [7].
The opportunistic fungal pathogen, Cryptococcus neoformans,i sa
major cause of morbidity and mortality in patients with impaired
CD4
+ T-cell function, particularly those with AIDS [9]. A family
of antigens, termed mannoproteins (MP), has been identified as the
immunodominant antigens which stimulate T-cell responses to C.
neoformans in patients recovered from cryptococcosis and in
experimentally infected mice [10]. MP have extensive N-and O-
linked mannosylation, which serve as ligands for MR and DC-
SIGN on DCs [10–12]. DCs can internalize, process and present
MP in the context of the MHC II to CD4
+ T-cells [13].
While MP are promising vaccine candidates, mice that were
administered MP with Ribi adjuvant system were only partially
protected from subsequent challenge with C. neoformans [14].
Perhaps due to its capacity for Th1 skewing, immune responses
appear to be a bit more vigorous when MP are administered with
complete Freund’s adjuvant [15]. However, because Freund’s
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skewing adjuvants are under investigation, including CpG [16].
Indeed, administration of CpG alone has salutary effects in murine
models of cryptococcosis [17–19]. Given the potential of CpG as
an adjuvant in an MP-based vaccine against cryptococcosis, we
studied the responses of murine DCs following stimulation with
MP alone and in combination with CpG. We found that that the
two stimuli acted synergistically to induce proinflammatory
cytokines and chemokines and to promote an MHC II-restricted,
antigen-specific CD4
+ T-cell response. Moreover, synergy re-
quired the interaction of mannose residues on MP with MR on
DC.
Results
Murine cDCs were stimulated with MP, CpG, or MP+CpG and
monitored for production of TNF-a. This cytokine plays a critical
role in host defenses against cryptococcosis [20]. MP+CpG 1826, a
B-type ODN which stimulates murine cDCs, synergized to
produce more TNF-a than MP or CpG alone (Figure 1 A). This
effect was more than additive, as MP stimulation alone produced
little TNF-a. Maximum TNF-a was observed when 10 mg/ml MP
was combined with 10 mg/ml CpG. Concentrations of MP higher
than 10 mg/ml, when combined with CpG, did not stimulate
greater cytokine responses (data not shown). Thus, the dose of
10 mg/ml of MP was used in subsequent cytokine studies on cDCs.
The combination of MP+CpG stimulated TNF-a responses
comparable to that seen with 1 mg/ml LPS (Figure 1 B). The
control ODN 2138 (10 mg/ml), which contains GpC motifs in lieu
of CpG motifs, failed to stimulate cytokine release.
MP+CpG synergized to stimulate cDC production of IL-12p70,
as well as enhancing the production of other proinflammatory
cytokines, including IL-6, IL-12p40/p70, and IL-1a (Figure 2).
Furthermore, MP+CpG augmented the production of the
chemokines MIP-1a, KC, MCP-1, and IP-10. However,
MP+CpG also enhanced the production of the immunoregulatory
cytokines IL-10 and IL-13, although only relatively small amounts
of these cytokines were produced. Levels of IL-1b, IL-2, IL-4, IL-
5, IL-17, MIG, VEGF, FGF basic, GM-CSF, and IFN-c were
undetectable following stimulation of cDCs with LPS, MP, CpG,
and MP+CpG (data not shown).
MP consists of a protein core with extensive mannosylation. We
hypothesized that synergy of MP and CpG requires mannosyla-
tion. To test this hypothesis, we determined whether Saccharomyces
cerevisiae mannan, which consists of branched mannose chains,
could be substituted for MP in mediating synergy with CpG. We
found that this was indeed the case; mannan and MP each
synergized with CpG to boost IL-12p70 production by cDCs
(Figure 3 A). To further test the hypothesis, we compared the
synergistic stimulatory capacity of recombinant C. neoformans
MP98, a highly mannosylated MP produced in Pichia pastoris,
with a version that was chemically deglycosylated (DMP98) [21] .
Enhanced TNF-a was seen when the cDCs were stimulated with
MP98+CpG, but not DMP98+CpG (Figure 3 B). Together, these
data strongly suggest that the mannose residues are necessary for
synergy with CpG.
Next, the role of the MR, CD206, was addressed. cDCs from
MR KO mice were stimulated with MP, CpG, and MP+CpG.
There was a significant decrease in the amount of TNF-a
produced in MR KO cDCs stimulated with MP+CpG compared
to WT cDCs stimulated with the same amount of antigens
(Figure 3 C). This suggests a prominent role for the MR in driving
synergy.
TLR9, the ligand for CpG, utilizes MyD88 as its adapter
molecule to signal downstream events. Therefore, as expected,
neither CpG nor MP+CpG elicted any TNF-a from cDCs derived
from MyD88 KO mice (data not shown). To test whether this
synergy was a unique feature of the interaction of MP+CpG, we
next tested cDC cytokine release induced by TLR1/2, TLR3,
TLR4 and TLR7/8 ligands alone or in combination with MP.
Addition of MP resulted in stimulation of significantly greater
TNF-a release with all tested TLR ligands (Figure 4). This
demonstrates that MP+TLR ligand synergy also occurs following
stimulation of TLRs that are located on the cell surface (TLR1/2,
TLR4) and that utilize adapter molecules other than MyD88
(TLR3).
To address whether the observed synergy between MP+CpG
was due to a possible physicochemical interaction between MP
and CpG, WT cDCs were compared for their capacity to take up
Oregon Green-labeled MP and Alexa Fluor 647-labeled CpG
(Figure 5 A). However, uptake of CpG, as determined by flow
Figure 1. MP synergizes with CpG to stimulate cDCs to produce
TNF-a. (A) cDCs were stimulated with CpG ODN 1826 (0, 1, or 10 mg/
ml) and/or MP (0, 1, or 10 mg/ml). Supernatants were collected 24 hours
later and TNF-a concentrations determined by ELISA. Data are
means6SEM of a representative experiment performed in singlicate.
A second experiment yielded similar results. (B) MP+CpG synergize to
produce more TNF-a than MP or CpG alone. Data represent mean-
s6SEM of 6 independent experiments, each performed in singlicate.
p,0.001 comparing MP alone or CpG alone with MP+CpG by one way
ANOVA with Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0002046.g001
Stimulation of DC by MP & CpG
PLoS ONE | www.plosone.org 2 April 2008 | Volume 3 | Issue 4 | e2046Figure 2. MP synergizes with CpG to stimulate cDC to produce proinflammatory cytokines, chemokines, and immunoregulatory
cytokines. cDCs were stimulated as in Figure 1. Data are means6SEM of 4 independent experiments. p,0.001 comparing MP alone with MP+CpG
and p,0.05 comparing CpG alone with MP+CpG for IL-6 and IL-12p40/p70. p,0.001 comparing MP alone with MP+CpG and p,0.01 comparing CpG
alone with MP+CpG for KC and MCP-1. p,0.05 comparing MP alone or CpG alone with MP+CpG for MIP-1a.p ,0.01 comparing MP alone with
MP+CpG for IP-10. p,0.01 comparing MP alone or CpG alone with MP+CpG for IL-10. p,0.001 comparing MP alone or CpG alone with MP+CpG for
IL-12p70 and IL-13. All statistical comparisons were by one way ANOVA with Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0002046.g002
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CpG does not appear to be ‘‘carried’’ by MP into the cell.
Nevertheless, by confocal microscopy, although MP and CpG can
be found in distinct compartments, some colocalization of CpG
and MP inside the cell is also evident (Figure 5 B). These data
demonstrating that MP and CpG traffic to similar vesicular
structures suggest a potential mechanism whereby the two stimuli
may synergize to stimulate cytokine production.
The above studies focused on cDCs. As plasmacytoid DCs
(pDCs) express high levels of TLR9 [22], we next examined
whether MP+CpG would synergize to stimulate murine pDC
cytokines. We found that CpG 2336 (1 mg/ml)+MP (1 mg/ml) led
to the production of IL-12p40 at levels significantly greater than
those induced by CpG (1 mg/ml) alone (Figure 6 A). CpG 2336 is
an A-type CpG which stimulates murine pDCs. As pDCs also
produce IFN-a in response to the A-type CpG 2336, we measured
IFN-a by ELISA and found that MP+CpG stimulated significantly
greater amounts of IFN-a from pDCs than CpG alone. (Figure 6
B). Of note, CpG 2336, at 10 mg/ml, induced high amounts of IL-
12p40 and IFN-a but the addition of MP did not lead to further
increases (data not shown). LPS failed to induce cytokine
production, which is consistent with the lack of expression of
TLR4 on pDC [22], and thus demonstrates the high purity of the
pDC population.
Finally, we sought to determine whether stimulation of cDCs
with MP+CpG would result in an enhanced response of antigen-
specific T-cells. For these studies, we utilized the MP-specific T-
cell hybridoma P1D6, which produces IL-2 when stimulated by
DCs presenting a peptide fragment of MP98 in an MHC II-
restricted fashion [12]. In the presence of MP alone, cDCs derived
from WT, MR KO, and TLR9 KO mice stimulated similar levels
of T-cell IL-2 production. However, stimulation of WT cDCs with
MP+CpG resulted in greatly enhanced IL-2 production compared
with stimulation with either agent alone (Figure 7). Synergy was
not observed with either MR or TLR9 KO cDCs.
Discussion
In this study, we demonstrate that MP from C. neoformans and
the TLR9 agonist CpG synergize to stimulate cDCs and pDCs to
produce proinflammatory cytokines and chemokines, many of
which (e.g., IL-12p70) are associated with induction of Th1-type
Figure 3. Mannose residues and the MR are critical for
synergistic stimulation of cDCs with MP and CpG. (A) cDCs were
incubated for 24 hours with 1 mg/ml LPS, Control ODN 2138 (10 mg/ml),
CpG ODN 1826 (10 mg/ml), mannan (1 mg/ml), mannan (1 mg/ml)+CpG
(10 mg/ml), MP (10 mg/ml), or MP (10 mg/ml)+CpG (10 mg/ml). Super-
natants were analyzed by ELISA for IL-12p70. p,0.001 comparing
mannan alone or CpG alone with mannan+CpG. p,0.001 comparing
MP alone or CpG alone with MP+CpG. (B) Same as figure 3a, except
additional stimuli were recombinant MP98 derived from Pichia pastoris
which was either deglycosylated (DMP98, 1 mg/ml) or left fully
mannosylated (MP98, 1 mg/ml). Data are from 3 independent experi-
ments, each performed in singlicate. p,0.001 comparing MP98 alone or
CpG alone with MP98+CpG. (C) cDCs were obtained from WT and MR
KO mice. Cells were incubated for 24 hours with 10 mg/ml MP, 10 mg/
ml CpG, or MP+CpG following which supernatants were analyzed by
ELISA. Results are means6SEM of 3 independent experiments each
performed in singlicate. p,0.001 comparing MP alone or CpG alone
with MP+CpG in WT cDCs. p.0.05 comparing CpG alone with MP+CpG
in MR KO cDCs. All statistical comparisons were by one way ANOVA
with Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0002046.g003
Figure 4. MP synergizes with multiple TLR ligands. cDCs were
incubated for 24 hours with 10 mg/ml MP, 10 mg/ml Pam3CSK4,1 0mg/
ml pI:C, 1 mg/ml LPS, 10 mg/ml imiquimod, and 10 ug/ml CpG.
Supernatants were collected and analyzed for TNF-a by ELISA. Data
represent means6SEM of 4 independent experiments, each of which
was performed in singlicate. p,0.001 comparing any TLR ligand alone
with the TLR ligand plus MP by the two-tailed paired t-test.
doi:10.1371/journal.pone.0002046.g004
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enhanced IL-2 production by MP-specific CD4
+ T-cells. Thus,
stimulation of the innate immune receptors by mannosylated
ligands and CpG has the potential to enhance and bias adaptive
immune responses.
We have previously demonstrated that the MR on DC
recognizes and internalizes mannose residues on MP [11,13].
Here these findings are extended to demonstrate that synergy of
MP with CpG also is dependent on mannose residues. Synergy
was abolished by deglycosylation of MP98 and could be replicated
if S. cerevisiae mannans were substituted for MP. DCs have multiple
receptors that recognize mannose, including DC-SIGN and the
SIGNR homologs [23]. However, as synergy was not observed
with cDCs from MR KO mice, the MR appears to mediate this
effect. Interestingly, in the absence of a TLR ligand, MP
stimulated similar amounts of IL-2 production from antigen-
specific T-cells co-cultured with either MR KO or WT cDCs.
However, when MP+CpG were added, IL-2 synergy occurred
only with WT cDCs. Taken together, these data imply that while
uptake, processing and presenting of MP can occur independently
of the MR, synergistic stimulation of T cells by MP and CpG
requires the MR.
Not surprisingly, MP plus CpG synergy in cDCs was also
dependent on TLR9 and its adapter protein MyD88, as evidenced
by the loss of synergistic TNF-a secretion when cDCs from TLR9
KO or MyD88 KO mice were utilized. However, the TLR9
agonist CpG is not the sole TLR ligand that can synergize with
MP to produce proinflammatory cytokines and chemokines.
Synergy was also observed with Pam3CSK4 (TLR1/2), pI:C
(TLR3), LPS (TLR4), and imiquimod (TLR7/8). This has
implications for the design of human vaccines because while
human pDCs express TLR9, human cDCs do not [22]. However,
both human cDCs and pDCs express other TLRs, including
TLR7/8.
We did not observe any appreciable induction of cytokines using
MP alone on both cDCs and pDCs. This is in contrast to one
study which utilized MP from a different cryptococcal strain [24].
Thus, an adjuvant was necessary for us to produce a proin-
flammatory milieu. Similarly, we have found that MP does not
stimulate upregulation of CD40, CD86, and MHCII on DC (Dan,
Kelly, Lee, and Levitz; submitted for publication). The addition of
CpG to MP resulted in upregulation of these maturation markers.
However, there was no ‘‘synergy’’ as the level of expression of
CD40, CD86, and MHCII induced by CpG was the same in the
presence or absence of MP (Dan and Levitz, unpublished data).
Other studies have demonstrated cooperative responses be-
tween TLRs and other PRRs in the production of cytokines and
chemokines by DCs [1]. For example, collaborative induction of
inflammatory responses to the fungi Candida albicans and
Pneumocystis carinii has been observed with TLR2 and Dectin-1
Figure 5. MP and CpG are taken up independently but can colocalize in intracellular compartments. (A) MP-OG (10 mg/ml) and 1 mM
CpG ODN 1826-AF647 were incubated with cDCs for 15 minutes and analyzed by flow cytometry. Plots are representative of two independent
experiments. The plot on the left demonstrates no effect of CpG AF647 on cellular uptake of MP-OG. The second plot demonstrates no effect of MP-
OG on cellular uptake of CpG AF647. (B) cDCs were incubated with 10 mg/ml MP-OG (green) and 1 mM CpG ODN 1826-AF647 (red) for 20 minutes
and then analyzed by confocal microscopy. Yellow pseudocolor represents areas of colocalization of MP and CpG within DCs.
doi:10.1371/journal.pone.0002046.g005
Stimulation of DC by MP & CpG
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phagocytes via both TLR4 and MR [28]. Triggering PRRs on
dendritic cells can generate proinflammatory cytokines and
chemokines which recruit and activate other effector cells to the
area of the invading organism. Ideally, this process then results in
killing of the invading organisms by the innate immune response
and/or generation of effective adaptive responses [29]. However,
it is important to note that MP plus CpG stimulated both
proinflammatory and antiinflammatory cytokines, and thus the in
vivo effects of cooperative stimulation of the MR and TLRs
cannot be predicted with certainty.
It is tempting to speculate that the observed synergy of
MP+CpG is dependent upon the triggering of distinct intracellular
signals, which then merge to activate NF-kB and IRFs, as has been
demonstrated following stimulation of Dectin-1 and TLR2 [30].
MR bears a tyrosine-based sorting motif within its cytoplasmic tail
which directs localization of antigen into endosomes [31].
However, whether ligation of MR triggers intracellular signaling
cascades is controversial, particularly as there are no known
intracellular signaling motifs in the MR [31]. Treatment of
macrophages with an anti-MR monoclonal antibody resulted in
production of mainly anti-inflammatory cytokines, including IL-10
[32]. However, Pneumocystis carinii-induced activation of NF-kB in
alveolar macrophages was inhibited by an anti-MR blocking
antibody [33]. The MR functions both in pathogen recognition
and as an endogenous receptor for secreted proteins [34]. Hence,
perhaps it makes teleological sense that stimulation of MRs should
not induce a strong proinflammatory response unless a ‘‘danger
signal’’ such as a TLR ligand is also present to alert the host to a
threatening situation.
The specific intracellular signaling pathways responsible for the
observed synergy of MP+CpG remain undefined. Our preliminary
studies indicate a role for phosphoinositide 3-kinases (PI3K), as in
four independent experiments, the PI3K inhibitors wortmannin
and LY294002 each reduced the synergistic production of TNF-a
in response to CpG and MP (Dan and Levitz, unpublished data).
PI3K have been implicated in signaling events mediated by
multiple TLRs, including TLR2, TLR3, TLR4, and TLR9, so
they could potentially mediate the observed synergy between MP
and other TLR ligands in DCs [35]. Future studies should help
clarify this issue.
It has been suggested that DCs ‘‘sample’’ phagosomal and
endosomal compartments and that those containing TLR ligands
are preferentially processed [36,37]. As our confocal microscopy
studies showed some colocalization of MP and CpG within DC
compartments, this may help explain the increased cytokine
production and antigen-dependent CD4
+ T-cell response when
DCs were costimulated. However, further studies will be necessary
to prove this theory, particularly as a significant amount of
internalized MP and CpG localized to distinct compartments.
Interestingly, synergistic stimulation of cytokine responses was seen
Figure 6. MP+CpG synergize to stimulate murine pDCs to
produce IL-12p40 and IFN-a. pDCs were incubated with MP (1 mg/
ml), CpG ODN 2336 (1 mg/ml), or MP (1 mg/ml)+CpG (1 mg/ml).
Supernatants were collected 40 hours later and analyzed by ELISA.
Data are means6SEM of a representative experiment performed in
singlicate. Two other experiments yielded similar results. p,0.001
comparing MP alone with MP+CpG and p,0.01 comparing CpG alone
with MP+CpG for both IL-12p40 and IFN-a by one way ANOVA with
Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0002046.g006
Figure 7. Addition of CpG to MP enhances IL-2 production by
an MP specific T-cell hybridoma (P1D6) via a mechanism
dependent on MR and TLR9. cDCs were generated from WT, MR KO
and TLR9 KO mice and incubated with P1D6 cells in the presence of the
indicated stimuli. MP and CpG were both added at 1 mg/ml. Data are
means6SEM and are representative of 3 independent experiments with
WT and MR KO cDCs and one experiment with TLR9 KO cDCs. p,0.001
comparing MP alone or CpG alone with MP+CpG in WT cDCs by one
way ANOVA with Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0002046.g007
Stimulation of DC by MP & CpG
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intracellular or plasma membrane TLRs. However, it remains to
be demonstrated whether TLR ligands other than CpG will
colocalize with MP in DCs.
The demonstration that TLR ligands synergize with MP has
broad implications for the choice of an adjuvant not only for
cryptococcal vaccines, but for other antigens with mannose
moieties. In particular, one recent study highlighted the efficacy
of targeting the MR and utilizing a TLR agonist as an adjuvant for
potential chemotherapy in human cancers [38]. The efficiency of
the immune response could be greater if the mannosylated
antigens and TLR ligands were packaged together so that they are
directed to the same compartment in the cell. A similar strategy
has been suggested for the design of vaccines containing multiple
TLR ligands [36]. It can be predicted though that because the
pattern of response varies depending on the individual PRR that is
stimulated, that different combinations of PAMPs will elicit distinct
responses. While our data lend strong support to the design of
vaccines that combine mannosylated antigens with TLR ligands,
ultimately the utility of such an approach will require in vivo
testing.
Materials and Methods
Reagents
MP was prepared as described [14] from culture supernatants of
C. neoformans acapsular strain Cap 67 (ATCC 52817). The
preparation had an endotoxin content of 0.020 EU/mg, as
detected by the Limulus amebocyte lysate assay (Associates of
Cape Cod, East Falmouth, MA). ODN 1826 (B-type ODN), ODN
2138 (B-type negative control ODN, containing GpC rather than
CpG sequences), and ODN 2336 (A-type ODN) were purchased
from Coley Pharmaceuticals. Mannan was obtained from Sigma
Aldrich. C. neoformans MP98 was expressed recombinantly in P.
pastoris and purified as described [21]. MP98 was deglycosylated
(DMP98) by treatment with trifluoromethanesulfonic acid using a
commercial kit (GlycoProfile IV chemical deglycosylation kit,
Sigma) followed by gel purification, as in previous studies [21].
Deglycosylation was confirmed by loss of periodic acid-Schiff
staining and an increase in mobility on SDS-PAGE. Pam3CYSK4,
polyinosine-polycytidylic acid (pI:C), and imiquimod were ob-
tained from Invivogen. LPS from Escherichia coli O111:B4 (Sigma)
was repurified via a modified phenol re-extraction technique to
yield LPS with only TLR4 agonist activity [39].
Mice
C57BL/6 mice were obtained from Jackson Laboratories. MR
(CD206) KO mice were a gift from M.C. Nussenzweig (The
Rockefeller University). MyD88 KO and TLR9 KO mice were a
gift from S. Akira (Osaka University). All KO mice were
backcrossed to a C57BL/6 background for at least ten
generations. All animal studies were approved by The University
of Massachusetts Medical School’s Institutional Animal Care and
Use Committee.
Bone marrow-derived cDCs
Murine bone marrow-derived cDCs were generated following
the protocol by Lutz et al. [40], with slight modifications. Briefly,
cells obtained from the femurs and tibias of mice were cultured at
2610
6 cells per 100615 mm Petri dishes in 10 mL of R10 media
containing RPMI 1640 supplemented with 10% FBS (Tissue
Culture Biologicals, Tulare, CA), 100 U/ml penicillin, 100 mg/ml
streptomycin, 2 mM L-glutamine, 50 mM 2-mercaptoethanol.
R10 media were supplemented with 10% supernatant obtained
from the GM-CSF producing J558L cell line at 37u C and 5%
CO2. Media were replenished on days 3, 6, and 8. On day 9, non-
adherent cells were harvested and the cDCs were purified by two
passages over an LS column (Miltenyi Biotec) using CD11c
+
magnetic beads. The cDCs were .90% CD11c
+ CD11b
+ B220
2,
as determined by flow cytometry.
Bone marrow-derived pDCs
To generate pDCs, bone marrow-derived DCs were isolated
from femurs and tibias and the RBCs were lysed with RBC lysing
buffer (Sigma). Cells were washed 3 times and resuspended in 12
mLs R10 media supplemented with 20 ng/ml recombinant mouse
fms-related tyrosine kinase 3 ligand (Flt3L) (R&D). Four mL were
added per well of a 6 well plate and the cells were cultured for
7 days without changing the medium. Non-adherent cells were
harvested and sorted for CD11c
+, CD11b
2, B220
+ on FACSAria
cell sorter (BD Biosystems). Mouse pDC purity was $98%.
Cytokine ELISAs
Purified cDCs (2610
5) were incubated with the indicated
stimulus for 24 hours in R10 medium containing 20 mg/ml
polymyxin B (except for the LPS-stimulated groups) in 48 well
non-tissue cultured treated plates. Cell supernatants were collected
and analyzed by ELISA using IL-12p70 and TNF-a ELISA kits
(eBioscience). Fibroblast growth factor basic, GM-CSF, IFN-c, IL-
1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-
c-inducible protein 10, KC, MCP-1, MIG, MIP-1a, TNF-a, and
vascular endothelial growth factor were analyzed on a Bio-Plex
Luminex-100 station at the Baylor Luminex National Institute of
Allergy and Infectious Diseases core facility (Dallas, TX). For
pDCs, cells (5610
4/well) were incubated with the indicated stimuli
for 40 hours in R10 in 96 well flat bottom plates. Supernatants
were collected and analyzed by ELISA for murine IL-12p40 (BD
Bioscience) and IFN-a (PBL Biomedical Laboratories).
Flow Cytometry and Confocal Microscopy
MP was labeled with Oregon green in sodium bicarbonate
buffer (pH 8.0) following the manufacturer’s protocol (Molecular
Probes). Excess Oregon green was removed using a G10 Sephadex
column (Sigma Aldrich). MP-OG was then dialyzed overnight
against water. Alexa Fluor 647 labeled CpG ODN 1826 was
obtained from Integrated DNA Technologies and dissolved in
DNase-, RNase-free distilled water (Invitrogen). Flow cytometric
data were acquired using an LSR Flow Cytometer from BD
Biosciences and analyzed using WinMDI software (Scripps
Research Institute). Confocal microscopy was performed on a
Leica SP2 AOBS confocal microscope (Leica Microsystems) using
35 mm glass bottom dishes (MatTek).
Stimulation of an MP-specific T cell Hybridoma
CD11c
+ purified cDCs (1610
4/well) derived from WT, MR
KO, and TLR9 KO were co-cultured with the MP-specific T-cell
hybridoma, P1D6 (1610
5/well) for 24 hours in the presence of no
stimulus, MP, CpG or MP+CpG [12]. Supernatants were
collected and assayed for IL-2 by bioassay using the IL-2-
dependent CTLL-2 cell line.
Statistics
GraphPad Prism Software was used for statistical analyses.
When comparing three or more groups, a one way ANOVA with
a Tukey multiple correction test was performed. For the
experiments in figure 4 comparing TLR agonists in the presence
and absence of MP, a two-tailed paired Student t-test with a
Stimulation of DC by MP & CpG
PLoS ONE | www.plosone.org 7 April 2008 | Volume 3 | Issue 4 | e2046Bonferroni correction was performed. Significance was defined as
p,0.05.
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